{'fraction_non_alphanumeric': 0.023993808049535603, 'fraction_numerical': 0.015479876160990712, 'mean_word_length': 5.246376811594203, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Initial increase of plasma radioactive calcium after intravenous injection of calcitonin in man.

1. An intravenous infusion of calcitonin produced a sudden increase of plasma radioactivity after intravenous administration of 47 Ca in man. 2. This effect was noted a few minutes before the well-known decrease of plasma calcium concentration. 3. A mathematical evaluation of this phenomenon demonstrated that: (a) it was significant in normal subjects, provided patients were given calcitonin 60–360 min after the intravenous injection of 47 Ca; (b) it was generally not significant in patients with senile osteoporosis or osteomalacia; (c) it was particularly evident in patients with generalized Paget9s disease or multiple myeloma. 4. Surface measurements performed on soft tissues and bone demonstrated a transient, simultaneous decrease of 47 Ca radioactivity from bone. 5. The increase in plasma radioactivity implies a shift of 47 Ca from reservoirs with high specific radioactivity, possibly bone cells, to the circulation. 6. According to these data two different mechanisms of action of calcitonin could be considered: an early effect on bone cells producing a shift of calcium to the circulation, and the well-known later hypocalcaemic effect through diminution of bone resorption.